DK1337525T3 - Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol - Google Patents
Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazolInfo
- Publication number
- DK1337525T3 DK1337525T3 DK01998545.6T DK01998545T DK1337525T3 DK 1337525 T3 DK1337525 T3 DK 1337525T3 DK 01998545 T DK01998545 T DK 01998545T DK 1337525 T3 DK1337525 T3 DK 1337525T3
- Authority
- DK
- Denmark
- Prior art keywords
- lansoprazole
- crystal
- crystallizing
- production method
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000367757 | 2000-12-01 | ||
PCT/JP2001/010462 WO2002044167A1 (en) | 2000-12-01 | 2001-11-30 | Process for the crystallization of (r)- or (s)-lansoprazole |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1337525T3 true DK1337525T3 (da) | 2011-09-19 |
Family
ID=18838123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01998545.6T DK1337525T3 (da) | 2000-12-01 | 2001-11-30 | Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol |
Country Status (17)
Country | Link |
---|---|
US (2) | US7285668B2 (da) |
EP (2) | EP2345650A1 (da) |
KR (3) | KR100939948B1 (da) |
CN (1) | CN1254473C (da) |
AT (1) | ATE511508T1 (da) |
AU (1) | AU2002218506A1 (da) |
CA (1) | CA2436825C (da) |
CY (1) | CY1112347T1 (da) |
DK (1) | DK1337525T3 (da) |
ES (1) | ES2367419T3 (da) |
HK (1) | HK1054380B (da) |
HU (1) | HU229356B1 (da) |
NO (1) | NO326019B1 (da) |
PL (3) | PL214684B1 (da) |
PT (1) | PT1337525E (da) |
TW (1) | TWI290922B (da) |
WO (1) | WO2002044167A1 (da) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020027315A1 (en) * | 2000-03-10 | 2002-03-07 | Parker Gerard E. | Low-firing temperature method for producing Al2O3 bodies having enhanced chemical resistance |
DK1293507T3 (da) | 2000-05-15 | 2007-12-27 | Takeda Pharmaceutical | Fremgangsmåde til fremstilling af krystaller |
MXPA04009384A (es) * | 2002-03-27 | 2005-01-25 | Teva Pharma | Polimorfos de lansoprazol y proceso para la preparacion de los mismos. |
AU2003273000A1 (en) * | 2002-10-16 | 2004-05-04 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
CA2514575A1 (en) * | 2003-01-31 | 2004-08-12 | Teijin Pharma Limited | Crystal of (23s)-1.alpha.-hydroxy-27-nor-25-methylenevitamin d3-26,23-lactone and process for producing the same |
US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
AR045062A1 (es) * | 2003-07-18 | 2005-10-12 | Santarus Inc | Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas |
JP2006528182A (ja) * | 2003-07-18 | 2006-12-14 | サンタラス インコーポレイティッド | 薬学的製剤および酸に起因する消化器疾患の治療法 |
US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
WO2005076987A2 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
CA2561700A1 (en) * | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
JP5563735B2 (ja) | 2004-06-16 | 2014-07-30 | タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド | Ppi多回剤形 |
EP1681056A1 (en) * | 2005-01-14 | 2006-07-19 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for preparing lansoprazole |
CA2624179A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
EP1967183A4 (en) | 2005-12-28 | 2011-02-23 | Takeda Pharmaceutical | SOLID PREPARATION WITH CONTROLLED RELEASE |
KR100758600B1 (ko) | 2006-01-05 | 2007-09-13 | 주식회사 대웅제약 | 란소프라졸 결정형 a의 제조방법 |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
US9486446B2 (en) | 2006-12-28 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
WO2008087665A2 (en) * | 2007-01-18 | 2008-07-24 | Matrix Laboratories Ltd | Process for preparation of lansoprazole |
KR101303813B1 (ko) | 2007-04-16 | 2013-09-04 | 에스케이케미칼주식회사 | 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법 |
CN102014638A (zh) * | 2007-10-12 | 2011-04-13 | 武田制药北美公司 | 与食物摄入无关的治疗胃肠病症的方法 |
NZ593629A (en) * | 2007-12-18 | 2012-11-30 | Watson Pharma Private Ltd | Stable amorphous R-lansoprazole prepared by optically resolving racemic lansoprazole |
GEP20125649B (en) * | 2008-03-10 | 2012-09-25 | Takeda Pharmaceutical | Benzimidazole compound crystal |
US8362042B2 (en) * | 2008-05-14 | 2013-01-29 | Watson Pharma Private Limited | Stable R(+)-lansoprazole amine salt and a process for preparing the same |
US20100113527A1 (en) * | 2008-09-30 | 2010-05-06 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of dexlansoprazole |
WO2010056059A2 (en) * | 2008-11-14 | 2010-05-20 | Hanmi Pharm. Co., Ltd. | Novel crystalline dexlansoprazole and pharmaceutical composition comprising same |
IT1391776B1 (it) * | 2008-11-18 | 2012-01-27 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo |
WO2010095144A2 (en) * | 2009-02-04 | 2010-08-26 | Msn Laboratories Limited | Process for the preparation of proton pump inhibitors |
IT1392813B1 (it) | 2009-02-06 | 2012-03-23 | Dipharma Francis Srl | Forme cristalline di dexlansoprazolo |
US20110009637A1 (en) * | 2009-02-10 | 2011-01-13 | Dario Braga | Crystals of Dexlansoprazole |
WO2011004387A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | Process for the preparation of dexlansoprazole polymorphic forms |
IT1395118B1 (it) * | 2009-07-29 | 2012-09-05 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo cristallino |
EP2528912A1 (en) | 2010-01-29 | 2012-12-05 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline forms of dexlansoprazole |
EP2552904A1 (en) | 2010-03-31 | 2013-02-06 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
WO2011121546A1 (en) | 2010-03-31 | 2011-10-06 | Ranbaxy Laboratories Limited | Salts of dexlansoprazole and their preparation |
US20130216617A1 (en) | 2010-06-29 | 2013-08-22 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
PE20140005A1 (es) | 2010-12-03 | 2014-01-23 | Takeda Pharmaceutical | Tableta oralmente desintegradora |
MX2013007588A (es) | 2010-12-27 | 2013-08-09 | Takeda Pharmaceutical | Comprimido de desintegracion oral. |
WO2012104805A1 (en) | 2011-02-01 | 2012-08-09 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
EP2723728A1 (en) | 2011-06-21 | 2014-04-30 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
CN102234265B (zh) * | 2011-08-08 | 2013-11-20 | 天津市汉康医药生物技术有限公司 | 兰索拉唑化合物 |
TWI630002B (zh) | 2011-11-30 | 2018-07-21 | 武田藥品工業股份有限公司 | 乾塗覆錠 |
JP5934380B2 (ja) | 2011-12-29 | 2016-06-15 | インテル コーポレイション | 可変の深さ圧縮 |
WO2013140120A1 (en) | 2012-03-22 | 2013-09-26 | Cipla Limited | Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole |
WO2013179194A1 (en) | 2012-05-31 | 2013-12-05 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline dexlansoprazole |
KR20160010595A (ko) | 2013-05-21 | 2016-01-27 | 다케다 야쿠힌 고교 가부시키가이샤 | 구강내 붕괴정 |
CN103254174B (zh) * | 2013-06-05 | 2014-06-11 | 湖北济生医药有限公司 | 一种兰索拉唑化合物及其药物组合物 |
US9920196B2 (en) | 2013-06-20 | 2018-03-20 | Japan Polypropylene Corporation | Propylene-based block copolymer |
CN104958276A (zh) * | 2015-07-30 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗胃溃疡的药物兰索拉唑组合物胶囊 |
CN104997739A (zh) * | 2015-08-31 | 2015-10-28 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗消化***疾病的药物兰索拉唑组合物冻干粉针剂 |
CN105399728B (zh) * | 2015-12-20 | 2017-11-28 | 寿光富康制药有限公司 | 一种适用于工业化生产的右兰索拉唑的处理方法 |
CN106279107A (zh) * | 2016-08-10 | 2017-01-04 | 成都尚药科技有限公司 | 一种右旋兰索拉唑晶型的制备方法 |
CN106749182A (zh) * | 2016-11-08 | 2017-05-31 | 山东裕欣药业有限公司 | 一种右旋兰索拉唑晶型化合物及其制备方法 |
IT201700050223A1 (it) | 2017-05-09 | 2018-11-09 | Dipharma Francis Srl | Procedimento per la preparazione di dexlansoprazolo cristallino |
WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
DK171989B1 (da) * | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler |
SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
HRP960232A2 (en) | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
JPH1085502A (ja) * | 1996-09-19 | 1998-04-07 | Konica Corp | 晶析方法 |
JP3828648B2 (ja) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | 2−(2−ピリジルメチルスルフィニル)ベンズイミダゾール系化合物の結晶およびその製造法 |
TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
TR199901101T2 (xx) * | 1996-11-22 | 1999-07-21 | The Procter & Gamble Company | Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler. |
EP1056457A4 (en) * | 1998-01-30 | 2006-10-25 | Sepracor Inc | S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE |
JP4536905B2 (ja) * | 1999-06-17 | 2010-09-01 | 武田薬品工業株式会社 | ベンズイミダゾール化合物の結晶 |
JP3283252B2 (ja) * | 1999-06-17 | 2002-05-20 | 武田薬品工業株式会社 | ベンズイミダゾール化合物の結晶 |
TWI289557B (en) * | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
CA2375091A1 (en) * | 1999-06-30 | 2001-01-11 | Takeda Chemical Industries, Ltd. | Crystals of benzimidazole compounds |
JP2001039975A (ja) * | 1999-07-26 | 2001-02-13 | Eisai Co Ltd | スルホキシド誘導体の結晶およびその製造法 |
AU6727700A (en) | 1999-08-25 | 2001-03-19 | Takeda Chemical Industries Ltd. | Process for the preparation of optically active sulfoxide derivatives |
EP1277752B1 (en) | 2000-04-28 | 2006-11-22 | Takeda Pharmaceutical Company Limited | Process for producing optically active sulfoxide derivative |
DK1293507T3 (da) | 2000-05-15 | 2007-12-27 | Takeda Pharmaceutical | Fremgangsmåde til fremstilling af krystaller |
CN1117747C (zh) * | 2000-06-19 | 2003-08-13 | 中国科学院成都有机化学研究所 | 光学纯兰索拉唑的制备方法 |
-
2001
- 2001-11-30 DK DK01998545.6T patent/DK1337525T3/da active
- 2001-11-30 PL PL362801A patent/PL214684B1/pl unknown
- 2001-11-30 KR KR1020087028441A patent/KR100939948B1/ko active IP Right Grant
- 2001-11-30 CA CA2436825A patent/CA2436825C/en not_active Expired - Lifetime
- 2001-11-30 PL PL409463A patent/PL409463A1/pl unknown
- 2001-11-30 WO PCT/JP2001/010462 patent/WO2002044167A1/en not_active Application Discontinuation
- 2001-11-30 EP EP10177469A patent/EP2345650A1/en not_active Ceased
- 2001-11-30 HU HU0400781A patent/HU229356B1/hu unknown
- 2001-11-30 KR KR1020097023619A patent/KR20100002278A/ko not_active Application Discontinuation
- 2001-11-30 PL PL399787A patent/PL399787A1/pl unknown
- 2001-11-30 EP EP01998545A patent/EP1337525B8/en not_active Expired - Lifetime
- 2001-11-30 US US10/432,798 patent/US7285668B2/en not_active Expired - Lifetime
- 2001-11-30 ES ES01998545T patent/ES2367419T3/es not_active Expired - Lifetime
- 2001-11-30 PT PT01998545T patent/PT1337525E/pt unknown
- 2001-11-30 KR KR1020037007334A patent/KR100887912B1/ko active IP Right Grant
- 2001-11-30 AU AU2002218506A patent/AU2002218506A1/en not_active Abandoned
- 2001-11-30 AT AT01998545T patent/ATE511508T1/de active
- 2001-11-30 TW TW090129629A patent/TWI290922B/zh not_active IP Right Cessation
- 2001-11-30 CN CNB018198163A patent/CN1254473C/zh not_active Expired - Lifetime
-
2003
- 2003-05-28 NO NO20032437A patent/NO326019B1/no not_active IP Right Cessation
- 2003-09-13 HK HK03106568.6A patent/HK1054380B/zh not_active IP Right Cessation
-
2007
- 2007-09-07 US US11/899,918 patent/US20080306118A1/en not_active Abandoned
-
2011
- 2011-08-24 CY CY20111100809T patent/CY1112347T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1337525T3 (da) | Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol | |
DK0573848T3 (da) | Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler | |
DE60105113D1 (de) | Verfahren zur Herstellung von einem Kristallepoxid | |
DE60235089D1 (de) | Verfahren zur stabilisierung von reduziertem coenzym q10 und verfahren zur sauren kristallisation | |
NO20005660D0 (no) | Nye mellomprodukter og fremgangsmåter for fremstilling av optisk aktive oktansyrederivater | |
DE60316791D1 (de) | Verfahren zur aufreinigung von lanzoprazol | |
HUP0302530A2 (hu) | Eljárás 2-nitro-4-metilszulfonil-benzoesav tisztítására | |
DE60104687D1 (de) | Mikrofiltration unter verwendung von aktivkohle | |
DK1213294T3 (da) | Fremgangsmåde til rensning af phosphatidylserin | |
DE50104094D1 (de) | Verfahren zur Herstellung von reinem Triethylendiamin (TEDA) | |
BR9913720A (pt) | Processo de purificação por cristalização ourecristalização de ácidos carboxìlicos | |
ATE115547T1 (de) | Verfahren zur reinigung von tetraacetylethylendiamin (taed). | |
DK0782996T3 (da) | Fremgangsmåde til fremstilling af N-biphenylmethylthiadiazolinderivat eller salt deraf og mellemprodukt til fremstilling af | |
DK1307101T3 (da) | Fremgangsmåde til fremstilling af et biocidtkoncentrat | |
ATE88999T1 (de) | Reinigung von isothiazolonen. | |
DK1091001T3 (da) | Fremgangsmåde til rensning af S-adenosyl-L-methionin og til fremstilling af farmaceutiske acceptable salte deraf | |
DE60019723D1 (de) | Eine methode zur herstellung von verbindungen der formel 1 und derivaten | |
TH57580B (th) | วิธีการผลิตผลึก | |
ATE387420T1 (de) | Verfahren zur reinigung von einer alpha- hydroxysäure auf industrieller basis | |
DE60233541D1 (de) | Verfahren zur Reinigung von 5'-geschützten 2'-Deoxypurin Nukleosiden | |
DE60023232D1 (de) | Kristallisierung von Alpha-L-Aspartyl-L-Phenylalaninmethylester aus übersättigten Lösungen | |
DK1462439T3 (da) | Hidtil ukendte stabile krystaller af substitueret phenylpropionsyrederivat og fremgangsmåder til fremstilling af den samme | |
DE602004028230D1 (de) | Verfahren zur Reinigung und zur Herstellung von Phosphorsäure | |
ATE264314T1 (de) | Benzoxazol-derivate, verfahren zu ihrer herstellung und herbizide | |
DE60201145D1 (de) | Verfahren zur Reinigung von 5'-geschützten Thymidinen |